Syndax Pharmaceuticals (SNDX) Expected to Announce Earnings on Thursday

Syndax Pharmaceuticals (NASDAQ:SNDX) is expected to release its Q1 2026 results before the market opens on Thursday, April 30th. Analysts expect Syndax Pharmaceuticals to post earnings of ($0.59) per share and revenue of $72.6640 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Monday, May 4, 2026 at 4:30 PM ET.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Thursday, February 26th. The company reported ($0.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.14). The company had revenue of $68.73 million for the quarter, compared to the consensus estimate of $64.75 million. Syndax Pharmaceuticals had a negative return on equity of 206.62% and a negative net margin of 165.37%.The business’s quarterly revenue was up 792.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.10) EPS. On average, analysts expect Syndax Pharmaceuticals to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Syndax Pharmaceuticals Stock Performance

NASDAQ SNDX opened at $21.39 on Monday. The firm’s fifty day moving average price is $22.99 and its two-hundred day moving average price is $20.27. The stock has a market cap of $1.89 billion, a PE ratio of -6.50 and a beta of 0.41. Syndax Pharmaceuticals has a fifty-two week low of $8.58 and a fifty-two week high of $25.59. The company has a debt-to-equity ratio of 5.32, a quick ratio of 4.12 and a current ratio of 4.40.

Analysts Set New Price Targets

Several analysts have recently weighed in on SNDX shares. Wall Street Zen upgraded Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, March 8th. Jefferies Financial Group restated a “buy” rating and set a $40.00 price target (down from $48.00) on shares of Syndax Pharmaceuticals in a report on Monday, March 30th. Stifel Nicolaus set a $45.00 price target on Syndax Pharmaceuticals in a report on Friday, February 27th. Mizuho reduced their price target on Syndax Pharmaceuticals from $45.00 to $43.00 and set an “outperform” rating on the stock in a report on Tuesday, March 31st. Finally, JPMorgan Chase & Co. boosted their price target on Syndax Pharmaceuticals from $33.00 to $45.00 and gave the stock an “overweight” rating in a report on Monday, March 9th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $40.33.

Insider Transactions at Syndax Pharmaceuticals

In related news, CEO Michael A. Metzger sold 17,159 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $21.03, for a total value of $360,853.77. Following the sale, the chief executive officer directly owned 491,690 shares in the company, valued at $10,340,240.70. This represents a 3.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Keith A. Goldan sold 3,410 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $21.03, for a total value of $71,712.30. Following the completion of the sale, the chief financial officer owned 140,429 shares in the company, valued at $2,953,221.87. The trade was a 2.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 30,063 shares of company stock worth $628,332 in the last quarter. Corporate insiders own 4.10% of the company’s stock.

Institutional Trading of Syndax Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in SNDX. Bank of America Corp DE boosted its holdings in Syndax Pharmaceuticals by 33.7% in the second quarter. Bank of America Corp DE now owns 3,838,872 shares of the company’s stock valued at $35,951,000 after acquiring an additional 967,873 shares during the last quarter. Qube Research & Technologies Ltd boosted its holdings in Syndax Pharmaceuticals by 99.5% in the second quarter. Qube Research & Technologies Ltd now owns 1,665,916 shares of the company’s stock valued at $15,601,000 after acquiring an additional 831,067 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its position in Syndax Pharmaceuticals by 126.8% during the second quarter. Adage Capital Partners GP L.L.C. now owns 1,432,440 shares of the company’s stock valued at $13,415,000 after acquiring an additional 800,800 shares during the last quarter. Ensign Peak Advisors Inc boosted its position in Syndax Pharmaceuticals by 97.6% during the fourth quarter. Ensign Peak Advisors Inc now owns 1,598,544 shares of the company’s stock valued at $33,585,000 after acquiring an additional 789,480 shares during the last quarter. Finally, State Street Corp boosted its position in Syndax Pharmaceuticals by 19.3% during the fourth quarter. State Street Corp now owns 4,596,552 shares of the company’s stock valued at $96,574,000 after acquiring an additional 743,003 shares during the last quarter.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.